

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

## Product Datasheet

### Recombinant 2019-nCoV Papain-Like Protease EBT-EPT114

Article Name	Recombinant 2019-nCoV Papain-Like Protease
Biozol Catalog Number	EBT-EPT114
Supplier Catalog Number	EPT114
Alternative Catalog Number	EBT-EPT114-50
Manufacturer	ELK Biotechnology
Category	Proteine/Peptide
Product Description	Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed....
Molecular Weight	Molecular weight: 35.8 KDa. Apparent molecular weight: 34 KDa, reducing conditions
UniProt	QHD43415.1
Purity	Greater than 95% as determined by reducing SDS-PAGE.

Application Notes

Biological activity: Measured by its ability to convert the fluorogenic peptide substrate, Arg-Leu-Arg-Gly-Gly-AMC (RLRGGAMC) to RLRGG and 7-amino-4-methylcoumarin (AMC). The Specific Activity is 241.7 pmol/min/ $\mu$ g. Background: Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV. PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits, specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity. In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons